Alexandra Dr. Goll
Advisor Life Sciences Fcf Fox Corporate Finance @Biopharma Advisory
Signup · Get unlimited contacts
WORK HISTORY
Advisor Life Sciences Fcf Fox Corporate Finance @Biopharma Advisory
Munich, DE
Strategic advisor to life sciences companies on financing, growth, and capital market access. Focus: Investor readiness, fundraising, M&A, and ESG. Close collaboration with leadership teams and healthcare investors. Role delivered as part of BioPharma Advisory.
EDUCATION
Freie Universität Berlin (Free University of Berlin)
Degree in Pharmacy , Pharmaceutical Sciences
Marburg University
Dr. (Ph.D), Molecular Pharmacology
ABOUT ALEXANDRA DR. GOLL
Strategic Board Leadership | Biopharma Growth | ESG & Sustainability | International GovernanceWith over 30 years of international experience in the pharmaceutical and biotech sectors, I serve as a certified Non-Executive Board Member and ESG specialist (SAIF-NE, QAIF / Deutsche Börse), with a strong focus on M&A, IPO readiness, sustainable growth, and strategic positioning.Throughout my career, I have led cross-functional teams and advised C-level executives on investment strategies, global expansion, and transformational deals - including multiple successful M&A transactions, IPOs, and 11 portfolio company exits.My professional background includes: Head of Business Development at Calliditas Therapeutics AB, leading up to its acquisition by Asahi Kasei in 2024, including cross-functional due diligence, in-licensing and out-licensing in rare nephrology. Managing & General Partner at TVM Capital, where I raised over €850 million across three fund generations and supported 18 portfolio companies - achieving 11 successful exits, including: Pharmasset Inc. → acquired by Gilead ($11B) Albireo Pharma Inc. → acquired by Ipsen ($952M) Idenix Inc. → acquired by Novartis ($500M) EUSA Ltd. → acquired by Jazz Pharmaceuticals ($600M) Arrow Ltd. → acquired by AstraZeneca ($150M) Actelion Ltd. → acquired by Johnson & Johnson ($30B) Strategic leadership at Roche Global Business Leader for HIV/CMV Member of the Amgen/Roche Neupogen® Joint Team for global launch and commercialization.I am certified in Supervisory Board Governance & ESG (SAIF-NE, QAIF / Deutsche Börse) and hold an updated Non-Executive Board Member Certification (Deutsche Börse).As Jury Member for the German President\'s Award for Innovation in Science and Technology (Deutscher Zukunftspreis) and through other honorary mandates, I remain deeply committed to supporting innovation, impact, and good governance.I am currently open to contributing my expertise to international board mandates and advisory roles where strategic transformation, stakeholder alignment, and sustainable leadership are key drivers for long-term success.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.